Why Kedrion BioPharma
Discover RYPLAZIM, the first FDA-approved treatment for Plasminogen Deficiency Type 1, a multi-systemic disease that can manifest through recurrent conjunctivitis unresponsive to standard care.
Description
Kedrion is a global biopharmaceutical company producing plasma-derived therapies to treat and prevent rare diseases. Its product RYPLAZIM® is the first FDA-approved treatment for PLGD-1, a rare genetic disorder causing fibrous lesions on mucous membranes, most commonly manifesting in the eyes. About 81% of patients show eye lesions as their primary symptom, though lesions can affect other organs as well. PLGD-1 impacts ~500 people in the U.S., but the disorder is often underdiagnosed according to experts.
Brands we will feature
Ryplazim
CATEGORIES
Launching New Product
Yes
Product Categories
Pharmaceutical/Vitamins
Segment
Eyecare
COMPANY CONTACTS
https://www.kedrion.us/
l.ranno@kedrion.com
+15515749090
ADDRESS
Parker Plaza, 400 Kelby Street, 11th Floor
Fort Lee
New Jersey
07024
United States